Do saliva-based nano-biochip tests provide a feasible and rapid screening method for acute myocardial infarction in prehospital settings?
Saliva-based nano-biochip tests may serve as a feasible, rapid point-of-care screening tool for acute myocardial infarction in prehospital settings, complementary to ECG.
Complementary to ECG, saliva-based tests within lab-on-a-chip systems may provide a convenient and rapid screening method for cardiac events in prehospital stages for AMI patients.
Floriano et al. (Fri,) studied this question.